manilatimes

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

46% confirmed objective response rate (ORR) and 92% disease control rate (DCR) observed with MICVO as monotherapy in 2L+ R/M HNSCC at 5.4 mg/kg 71% confirmed ORR and 100% DCR observed with MICVO in ...
Seeking Alpha

Pyxis Oncology, Inc. (PYXS) Discusses Preliminary Phase 1 Data for MICVO in Recurrent and Metastatic Head and Neck Squamous Cell Carcinoma Transcript

Ladies and gentlemen, thank you for standing by. Welcome to Pyxis Oncology MICVO Clinical Update Call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now ...
Nasdaq

Pyxis Oncology Highlights Promising Preclinical Data for Micvotabart Pelidotin (MICVO) in Cancer Therapy at AACR 2025

Pyxis Oncology, Inc. announced promising preclinical results for micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting extradomain-B fibronectin (EDB+FN). The data, to be presented at ...
Aktien Check

Pyxis Oncology Announces Positive Preliminary Phase 1 Data for Micvotabart Pelidotin (MICVO) in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

BOSTON, Dec. 18, 2025 (GLOBE NEWSWIRE) -- Pyxis Oncology, Inc. (Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced positive ...